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Activation ofthe murine c-myc promoter by murine c-Myb protein was examined in several cell lines by using
a transient expression system in which Myb expression vectors activate the c-myc promoter linked to a
chloramphenicol acetyltransferase reporter gene or a genomic 13-globin gene. Si nuclease protection analyses
confirmed that the induction of c-myc by c-Myb was transcriptional and affected both P1 and P2 start sites in
a murine T-cell line, ELA, and a myelomonocytic line, WEHI-3. Mutational analyses of the c-myc promoter
revealed that two distinct regions could confer Myb responsiveness in two T-cell lines, a distal site upstream of
P1 and a proximal site within the first noncoding exon. In contrast, only the proximal site was required for
other cell lineages examined. Five separate Myb-binding sites were located in this proximal site and found to
be important for c-Myb trans activation. DNA binding was necessary for c-myc activation, as shown by the loss
of function associated with mutation of Myb's DNA-binding domain and by trans-dominant repressor activity
of the DNA binding, trans-activation-defective mutant. The involvement of additional protein factors was
addressed by inhibiting protein synthesis with cycloheximide in a conditional expression system in which the
activity of presynthesized Myb was under the control of estrogen. These experiments indicate that de novo
synthesis of additional proteins was not necessary for c-myc trans activation. Together these data reveal two cell
lineage-dependent pathways by which c-Myb regulates c-myc; however, both pathways are mechanistically
indistinguishable in that direct DNA binding by Myb is required for activating c-myc whereas neither de novo
protein synthesis nor other labile proteins are necessary.
c-myb and c-myc are members of the nuclear proto-
oncogene family (13, 31, 32, 48). The expression of c-myc
mRNA and that of c-myb mRNA are each correlated with
cell proliferation and differentiation (13, 31, 32, 48). Expres-
sion of both proto-oncogenes increases dramatically when
lymphocytes are induced by mitogens or growth factors to
enter the cell cycle (13, 31, 32, 48, 52). They are expressed at
high levels in immature hematopoietic cells (13, 31, 32, 48,
52, 55) and decrease in a biphasic manner during terminal
differentiation (11, 12, 33, 34, 47, 53). Unlike c-myc, which is
ubiquitous, c-myb is preferentially expressed in cells of
hematopoietic origin, suggesting that c-Myb may be an
important regulator of hematopoiesis (13, 31, 32, 48, 55).
Experimental evidence supports respective roles for each
gene product in proliferation or differentiation control. An-
tisense DNAs (1, 16, 18, 21, 59) specific for either gene will
inhibit the proliferation of myeloid leukemia cells and T
cells. Constitutive overexpression of c-myc or c-myb mRNA
in vivo can prevent terminal differentiation in certain cell
types (11, 12, 33, 34, 47, 53) or enhance competence for cell
cycle progression (14, 54). Antisense oligonucleotides com-
plementary to c-myb mRNA can inhibit colony formation by
hematopoietic progenitor cells in vitro (19). Likewise, in
vivo inactivation of the c-myb gene results in defective
hematopoiesis (35). Recent data demonstrating that c-Myb
protein can activate c-myc gene expression (15, 36, 60)
suggest that their expression might be functionally linked
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rather than merely parallel. Therefore, it becomes impera-
tive to understand how the Myb protein might regulate
c-myc gene expression.
The c-Myb protein and its oncogenic homologs encoded
by the avian myeloblastosis virus (AMV) and E26 leukemia
virus appear to be transcriptional regulators (15, 24, 26, 37,
39, 46, 57). These proteins bind to specific DNA sequences,
and tandem repeats of these Myb regulatory elements
(MREs) will confer Myb-specific regulation to an unrespon-
sive promoter (17, 22, 36, 39, 46, 57, 60). Likewise, struc-
tural domains previously identified by their similarity to
known transcription factors have been shown to mediate
Myb's activation function (31, 48). For c-Myb, these do-
mains encode DNA-binding, trans-activator, and negative
regulatory functions (22, 25, 26, 28, 45, 46). The DNA-
binding domain is contained within an amino-terminal region
consisting of three 50-amino-acid repeats (31, 48). These
consecutive repeats (Rl, R2, and R3) contain a high percent-
age of basic amino acids and a conserved spacing of rela-
tively rare tryptophan residues (31, 45, 48). Of the three
repeats, only R2 and R3 are required for DNA binding (22,
45, 57). c-Myb contains a leucine zipper-like structure which
may be involved in interaction with other proteins (26). The
leucine zipper is contained within a larger negative regula-
tory domain whose deletion potentiates Myb's trans-activa-
tion function (24, 26, 46). A trans-activator domain has been
localized to an acidic region in the center of the c-Myb
protein (26, 46, 57). Transduced v-Myb proteins are invari-
ably truncated compared with c-Myb and appear to be more
potent transcriptional activators (20, 24, 25, 46, 57). Reten-
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tion of the DNA-binding and trans-activator domain con-
comitant with loss of the negative regulatory domain or a
small amino-terminal domain whose phosphorylation inhib-
its DNA binding in v-Myb proteins appears to be a key
feature in transformation (20, 24-26, 30, 46, 57).
Several cellular genes whose expression is regulated by
Myb have been identified. A current list of Myb-regulated
genes includes the human c-myb, lysozyme, Hsp70, mim-1,
MD-1, and CD4 genes (9, 28, 39, 40, 51). The presence of
Myb-binding sites in the promoter sequences of the mim-1
and c-myb genes appears, in part, to confer responsiveness
to the Myb protein (39, 40). Other genes may be regulated
indirectly. For example, the Hsp7O promoter can be trans
activated by DNA binding-defective Myb mutants (28).
Likewise, activation of the MD-1 gene is blocked by protein
synthesis inhibitors (9). Human and murine c-myc also
contain Myb-binding sites and are trans activated by c-Myb
(15, 36, 60); however, a direct link between Myb binding and
trans activation has not been established.
In this study, c-myc trans activation by c-Myb was ana-
lyzed in several cell lineages and lineage-specific mecha-
nisms were revealed. We further explored the activation
pathway in detail and showed that Myb binding to sites
within the first exon was required. Neither de novo protein
synthesis nor labile protein factors were necessary. We also
show that both P1 and P2 transcription was induced by Myb.
MATERIALS AND METHODS
Cell lines. The EIA, WEHI-3, L929, and BW5147 cell lines
were obtained from the Lineberger Comprehensive Cancer
Center Tissue Culture Facility. WEHI-231 was a gift of
David W. Scott, University of Rochester. The cell line
CH12.LX2 was provided by Geoffrey Haughton, University
of North Carolina. C33 cells were provided by Shannon
Kenney, University of North Carolina. The PU5-1.8 cell line
(ATCC TIB 61) was obtained from the American Type
Culture Collection, Bethesda, Md. EL4, WEHI-3, C33,
WEHI-231, L929, and BW5147 cells were all grown in
Dulbecco modified Eagle medium-H (DMEM-H) supple-
mented with 7.5% fetal calf serum, 100 p,g of streptomycin
per ml, 100 U of penicillin per ml, 0.1 mg of gentamicin per
ml, 1 mM sodium pyruvate, 1 mM nonessential amino acids,
2 mM glutamine, and 5 x 10-5 M 2-mercaptoethanol. 70Z/3,
402AX, CH12.LX2, and PU5.1R cells were grown in RPMI
1640 medium with the same supplements. ETA and WEHI-3
cells were also adapted to growth in phenol red-free
DMEM-H.
Plasmids. Construction of pMBgCAT, pSmBgCAT, pMB-
gCAT(2-36), pMBgXhCAT, and pMBg96CAT reporter
genes has been described elsewhere (2, 44). pMBgCAT
(AAw-Sm) and pMBgCAT(ABx-Sm) were constructed from
pMBgCAT by partial digestion with, respectively, the Al-
wNI and BstXI restriction enzymes, blunt ending the 3'
protruding ends with T4 DNA polymerase (Boehringer Mann-
heim), digestion with SmaI enzyme to release the AlwNI-
SmaI or BstXI-SmaI fragment, and ligation of the vector.
Reporter genes pMBg(AHd-Xh), pMBg(AHd-Nt), and
pMBg(ANt-Xh) were prepared from pMBgCAT by digestion
with the HindIII, NotI, orXhoI restriction enzyme to release
the corresponding HindIII-XhoI, HindIII-NotI, or NotI-
XhoI fragment; blunt ending the 5' protruding ends with
Klenow polymerase (Boehringer Mannheim); and vector
ligation. pSmBg(AHd-Xh) and pSmBg(ANt-Xh) are the cor-
responding deletions made in pSmBgCAT. pSVM(H)RCAT
contains the HindIII-BglII first exon fragment of c-myc
cloned downstream of the simian virus 40 (SV40) promoter.
The c-myc fragment contains 24 bp 5' of the P2 initiation site
but lacks the TATA box positioned 28 to 32 bp 5' of this start
site. Previous work has shown that the P2 start site is silent
and that transcription initiates from El and E2 start sites of
the SV40 promoter (58).
Site-specific mutants of putative Myb-binding sites 11 to
15 were made by Kunkel mutagenesis. Briefly, the BglII-
BglII fragment of the murine c-myc promoter was subcloned
into the BglII site of pSG5 (Stratagene). Template strands of
c-myc were prepared by M13K07 helper phage rescue in
Dut- Ung- CJ236 bacteria. Mutant oligonucleotides were
annealed, and second-strand synthesis was completed with
T4 DNA polymerase and deoxynucleoside triphosphates.
Circular templates were transformed into DHSa bacteria,
and mutant sequences were confirmed by dideoxy sequenc-
ing. The BglII-BglII fragment containing mutant Myb sites
was subcloned into pCAT(AEP) for transient transfections.
The wild-type Myb expression vector pRmb3SVneo and
frameshift mutant pJTmyb-fs were constructed as described
previously (15, 33). pJTmyb-fs lacks 7 bp 3' to the BstXI site
of murine c-Myb. Construction of c-Myb expression plas-
mids is as follows. The c-myb deletion mutants were first
constructed in a pBluescript SK vector containing the 2.2-kb
SmaI-BglII fragment from c-myb cDNA (4) in which SmaI
and BglII sites had been converted to HindIII and BamHI,
respectively. A HindIII-BamHI fragment containing each
mutated c-myb construct was gel purified from pBluescript
(Stratagene) or pGEM (Promega) vectors and cloned into the
Rous sarcoma virus vector pRmb3SVneo lacking the neo-
mycin gene. C-terminal deletions have the last 14 amino
acids and the termination codon. The map in Fig. 6A details
which amino acids have been deleted.
pNEO-AMV is an AMV v-myb expression vector which
contains a provirus, and its transcription is driven by the
long terminal repeat (25). pNEO-MAV-CLA is a control
plasmid in which the KYnI-XbaI v-myb fragment of pNEO-
AMV has been deleted and replaced by a ClaI linker (25).
pNEO-Myb-E is a v-myb-estrogen receptor fusion vector in
which the hormone-binding domain of the human estrogen
receptor has been fused in frame at the BalI site. The
carboxyl-terminal 16 amino acids of v-Myb was deleted in
this process. pNEO-Myb-E was derived from Neo-AMV-
AGE (25) and lacks gag and env sequences.
The pBS-globin plasmid (a gift of F. Fumari, University of
North Carolina) was constructed by inserting a blunt-ended
2.2-kb HindIII-XbaI fragment of pSP64HDB6 (29) which
contained the genomic sequence for the 3-globin gene into
the SmaI site of pBS+ (Stratagene). The murine c-myc
promoter was cloned into pBS-globin in two steps to make
pMyc-globin as follows. The BglII-BglII c-myc promoter
fragment from pMBgCAT was isolated, blunt ended with
Klenow polymerase, and ligated into the HincIl site of
pBS+ (Stratagene). The c-myc promoter was subsequently
removed as two fragments, XbaI-HindIII and HindIII-
HindIII, by digestion with XbaI and HindIII restriction
enzymes. Both fragments were ligated into the XbaI to
HindIII site of pBS-globin, and directional ligation was
confirmed by restriction mapping and double-stranded
dideoxy sequencing.
Transient transfections and chloramphenicol acetyltrans-
ferase (CAT) assays. All cells were seeded at low densities
and grown to log phase over 48 h prior to transfection.
Subconfluent monolayers of adherent WEHI-3, PU5-1.8,
and C33 cells were used. The cells were transfected with a
Bio-Rad gene pulser as described elsewhere (50). Transfec-
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TABLE 1. Cell-specific activation of c-myc-CAT expression by c-Myb
Cell line No. of Fold trans activation Requires MRR that isb:
Cell type name expts of c-myc by c-Myba Proximal Distal
Thymoma EL4 4 10.3 ± 0.5 + +
Thymoma BW5147 2 6.8 ± 1.8 + +
B lymphoma CH12 2 6.0 ± 0.2 ND ND
B lymphoma WEHI-231 4 9.4 ± 1.1 +
Pre-B lymphoma 70Z/3 3 1.2 ± 0.2 ND ND
(6.3 ± 0.5)
Myeloid PU5-1.8 3 36.0 ± 11.0 ND ND
Myeloid WEHI-3 3 21.4 ± 0.8 +
Embryonal carcinoma 402AX 4 3.0 ± 0.4 ND ND
Fibroblast L929 2 1.0 ± 0.3 ND ND
Epithelial C33 2 2.0 ± 0.3 ND ND
a All experiments were performed at a 1:1 ratio of Myb expression vector to pMBgCAT, except that 70Z/3 cells were transfected at both 1:1 and 4:1 ratios (the
latter result is shown in parentheses).
b ND, comparison was not done.
tions were generally performed in the same medium as was
used for growth. Cells grown in phenol red-free DMEM-H
for estrogen inductions were transfected in lx phosphate-
buffered saline with 7.5% fetal calf serum. Transfection
conditions were varied for each cell line to obtain optimal
transfection efficiency. EL4, BW5147, WEHI-231, 70Z/3,
and CH12.LX2 cells were electroporated at 240 V/960 ,uF.
All other cells were electroporated at 200 V/960 ,uF. Re-
porter plasmid concentrations used were generally 5 ,ug for
each cell line. The concentrations of Myb expression vectors
were usually 1:1 with the reporter gene except in estrogen
induction experiments, in which 10:1 ratios were used. Cells
were usually harvested for CAT assay 24 h posttransfection
unless otherwise indicated. CAT assays were performed as
described previously (50). The average enzyme assay was 1
to 2 h for EM4 and 4 to 24 h for other cell lines. Percent
acetylation was quantified by cutting out sections of the
thin-layer chromatography plate that corresponded to these
two forms, followed by scintillation counting.
RNA isolation and Si nuclease protection analysis. Cells
were harvested for RNA preparation 24 h posttransfection.
Total cellular RNA was recovered by lysis of transfected
cells in guanidine-thiocyanate and pelleting through CsCl as
described elsewhere (10). Uniformly labeled antisense
probes for murine c-myc were prepared by primer extension
of a single-stranded DNA template copy of the pMyc-globin
reporter plasmid. Template sense strands of pMyc-globin
were prepared by M13KO7 helper phage rescue. The glo-
bin-2 primer 5'-CAGTAACGGCAGACTTG-3' was an-
nealed to the first exon of human globin sequence, and
extension was carried out with Klenow polymerase using
[cc-32P]dATP, [a-32P]dCTP, and unlabeled dGTP and dTrP.
After digestion with SmaI, the strands were separated on a
4% denaturing polyacrylamide-urea gel. Probe bands were
excised and eluted in 0.5 M sodium acetate-0.1% sodium
dodecyl sulfate solution. Annealing reactions were set up
with 100,000 cpm of antisense DNA probe and 30 p,g of
RNA, and hybridization reactions were carried out over-
night at 58°C in a solution of 80% formamide, 40 mM PIPES
[piperzidine-N,N'-bis(2-ethanesulfonic acid)], 400 mM NaCl,
and 1 mM EDTA. Samples were digested with 400 U of S1
nuclease (Bethesda Research Laboratories) as described
previously (6) and then electrophoresed through a 4% dena-
turing polyacrylamide-urea gel along with HaeIII-cut
pBR322 markers. Protected bands were detected by autora-
diography.
Estrogen induction and cycloheximide treatment. The
pNEO-Myb-E expression vector converts the v-Myb protein
to an estrogen-inducible trans activator by fusing the hor-
mone-binding domain of the human estrogen receptor to a
carboxyl-truncated v-Myb protein. To measure estrogen
induction of the Myb-estrogen receptor fusion protein, EML
and WEHI-3 cells were adapted to growth in phenol red-free
DMEM-H (phenol red is a weak estrogen). It was not
necessary to remove estrogen from the fetal calf serum since
the concentrations were not high enough to interfere with
estrogen induction. EMA and WEHI-3 cells were induced
with a 1 ,uM final concentration of 1-estradiol (Sigma catalog
no. E-2758). To determine the need for de novo protein
synthesis in Myb function, estrogen-dependent activation of
the Myb-estrogen receptor fusion protein was measured in
the presence of the protein synthesis inhibitor cyclohexim-
ide. Cycloheximide was added 20 min prior to estrogen
induction to a final concentration of 50 p,g/ml, which inhib-
ited protein synthesis virtually completely as measured by
[35S]methionine incorporation (data not shown). Cells were
treated with estrogen and cycloheximide either alone or in
combination for 5 h prior to RNA preparation. Changes in
c-myc promoter activity were measured by S1 nuclease
protection analyses from the cotransfected pMyc-globin
plasmid.
RESULTS
The magnitude of Myb activation of the c-myc gene is cell
type dependent. Previously, we showed that a Rous sarcoma
virus long terminal repeat-driven c-Myb expression vector
could activate a 1.7-kb c-myc promoter fragment linked to a
CAT reporter gene in T cells (15). To determine whether the
trans activation of c-myc by c-Myb occurs in different cell
types, we examined the panel of murine cell lines shown in
Table 1. These plasmids were introduced at a 1:1 ratio and in
one case at a 4:1 ratio of the Myb expression vector to
pMBgCAT. Myb trans activation of c-myc (expressed as
fold trans activation) was normalized both to a frameshift
mutant of the Myb expression vector and to a promoterless
reporter gene.
The data in Table 1 clearly demonstrate that Myb can
activate the c-myc promoter in cell types other than T cells.
Some level of response was elicited in most cell types;
however, the magnitude of the responses clearly differed and
in general segregated according to cell type. Very modest
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responses were seen in nonhematopoietic 402AX embryonal
carcinoma (threefold), L929 fibroblast (onefold), and C33
epithelial (twofold) cells at 1:1 ratios of Myb to c-myc (Table
1). Moderate responses were seen in four lymphoid lines
from B and T lineages (6- to 10-fold). The strongest re-
sponses were elicited in two myelomonocytic cell lines (20-
to 30-fold), suggesting that myelomonocytic cells are espe-
cially permissive for this activation pathway.
The best activation was seen in cell lines which express
low endogenous levels of c-Myb, such as our WEHI-3 and
ELA lines. Background transcription due to endogenous
Myb is not high enough to interfere with trans activation.
70Z/3 pre-B cells contain high endogenous levels of c-myb
which may contribute to the poor trans activation at the
standard 1:1 ratio of Myb to c-myc. Higher concentrations of
c-Myb (at a 4:1 ratio) did result in sixfold trans activation. To
exclude the possibility that the magnitude of activation
varied with amount of c-Myb produced from the expression
vector, Myb proteins were immunoprecipitated from trans-
fected cell lines. Transfected Myb protein was efficiently
produced in even poorly responding cell lines such as 402AX
(data not shown). We conclude that the cell type influences
how well Myb activates c-myc.
Myb induces expression of Pl- and P2-initiated c-myc tran-
scripts. The above results represent the measurement of
CAT protein which may reflect changes in both RNA and
protein levels. Here, we determined whether Myb activation
caused specific increases in the levels of accurately initiated
c-myc mRNAs and, if so, whether these increases were
preferential for P1- or P2-initiated transcripts and whether
they varied with cell lineage. We have found that CAT
messages are unstable; hence, we cloned the 1.7-kb c-myc
promoter fragment into a P-globin test plasmid for the
purpose of stabilizing mRNA accumulation (3). This test
plasmid was transfected into ETA T cells or WEHI-3 my-
elomonocytic cells with full-length or frameshift mutant Myb
expression vectors. The RNA was isolated, and Si nuclease
protection was used to detect levels of endogenous and
plasmid-derived c-myc mRNAs. Plasmid-derived transcripts
were distinguished from endogenous c-myc transcripts by an
additional 118 bp of ,-globin sequence protected in the
RNA-DNA probe hybrids. A map of pMyc-globin and re-
sulting S1 hybrids is shown at the top of Fig. 1. Autoradiog-
raphy from short (lanes 1 to 3 and 7 to 9) and long (lanes 4 to
6 and 10 to 12) exposures is shown to better reveal changes
in P2 and P1 transcript levels, respectively, because the P2
signal is much stronger than the P1 signal (bottom of Fig. 1).
Myb effectively induced expression of c-myc mRNAs
from the cotransfected pMyc-globin plasmid in EL4 cells
(compare Myb-induced results in lanes 2 and 5 with unin-
duced results in lanes 1 and 4, respectively). Cells trans-
fected with a promoterless pBS-globin test plasmid did not
express Myc-globin transcripts, as expected (lanes 3 and 6).
Both P1 and P2 transcripts were induced by Myb. While it is
clear that both authentic transcripts are induced from the
test plasmid, changes in the expression of endogenous c-myc
gene were not detected, most likely because the transfected
cells, and hence Myb-induced transcripts, represent a small
fraction of the total cells. WEVEII-3 cells were also studied
since myelomonocytic cells are the preferred targets for Myb
transformation in chickens (25, 31, 48) and because c-myc
was effectively activated by Myb in these cells (Table 1).
Identical increases in P1 and P2 transcript levels were
observed (Fig. 1, lanes 7 to 12).
Since the Myb-induced accumulation of c-myc mRNAs
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FIG. 1. S1 nuclease protection assay of Myb-induced mRNAs in
EIA and WEHI-3 cells. A map of the pMyc-globin reporter plasmid
is shown at the top. Bg, BglII; Sm, SmaI. The dotted arrow
represents the labeled primer extension product used in hybridiza-
tion to transiently expressed mRNAs. S1 nuclease digestion yields
mRNA-probe hybrids of various lengths which are represented by
lines and labeled on the autoradiograph. Lanes 1 to 6 are samples
from EL-4 cells, and lanes 7 to 12 are samples from WEHI-3 cells.
pMyc-globin reporter was included in lanes 1, 2, 4, 5, 7, 8, 10, and
11, and control reporter pBS-globin was included in lanes 3, 6, 9,
and 12. The wild-type Myb expression vector, pRmb3SVneo, was
included in lanes 2, 3, 5, 6, 8, 9, 11, and 12, and frameshift mutant
vector pJTmyb-fs was included in lanes 1, 4, 7, and 10. The
autoradiograph was exposed for 5 days in lanes 1 to 3 and 7 to 9 and
2 weeks in lanes 4 to 6 and 10 to 12.
transcription with actinomycin D and compared the decay of
Myb-stimulated and unstimulated transcripts. The Myb-
induced transcripts from the test plasmid appeared to decay
with the same half-life (approximately 2 h) as noninduced
transcripts, suggesting that Myb induces c-myc transcription
(data not shown).
Deletion mapping of the murine c-myc promoter reveals
proximal and distal Myb response regions (MRRs) in the
lymphoid cell line EL4. Our analysis for potential MREs
revealed 16 potential sites spread throughout the murine
c-myc promoter which contain the critical AAC motif con-
tained in all Myb-binding sites (7, 23, 37, 56, 60). Ten
Myb-binding sites were located upstream of the P1 start site,
and six were located downstream of the P2 start site (num-
bered 1 to 16 in Fig. 2). Sites 3, 9, and 10 are perfect matches
to one of the three consensus sequences (7, 23, 37). Most
others have single base pair mismatches outside of the
critical AAC binding core. Site 4 contains, in addition to
AAC, an important GYCR motif recently defined by Howe
and Watson (23). Sites 13, 14, and 15 have several mis-
matches to the consensus, although sites 14 and 15 are
conserved with the human c-myc promoter and bind Myb
protein. Retention of a pyrimidine immediately 5' to the
AAC binding core was not considered critical in our analysis
because of recent data (60) showing that purines are func-
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FIG. 2. Myb-binding sites in the c-myc promoter. A map of the
c-myc promoter fragment present in pMBgCAT is shown. Sixteen
putative Myb-binding sites numbered from the 5' end of the gene are
listed. Their sequences are aligned according to the AAC consensus.
Starred sequences are perfect matches to a consensus (7, 22, 37).
Left arrow, coding strand; right arrow, noncoding strand. See text
for details.
tional in this context. Gel shift analyses with v-Myb protein
produced by Escherichia coli confirmed that Myb bound to
these putative binding sites (data not shown).
To define the relevant Myb-responsive target sequences,
deletions of the 1.7-kb c-myc fragment in the pMBgCAT
reporter plasmid were initially assayed for Myb responsive-
ness by 1:1 cotransfection with a c-Myb expression vector
into EL4 cells (Fig. 3A). To control for differences in
transfection efficiency, these and subsequent experiments
were repeated multiple times with at least two separate DNA
preparations. The c-Myb expression vector elicited a 10- to
15-fold-higher level of CAT activity from the pMBgCAT
reporter than a frameshift mutant of the Myb expression
vector or a promoterless reporter construct. Myb activation
of the mutant reporter genes was denoted as percent trans
activation relative to that of the wild-type pMBgCAT con-
struct, which was assigned a value of 100%. Removal of 716
bp of 5'-flanking myc sequences in pSmBgCAT yielded only
27% of the activation with pMBgCAT, whereas a pMBg-
CAT(96) construct truncated down to bp -179 relative to P1
was only slightly less active than pSmBgCAT. These data
suggest that an MRR(s) resides between bp -1140 and -424.
The effect of this region was consistently observed in EM4;
however, the quantitative effect varied somewhat among
experiments. Deletion of bp -868 and -424 in the
pMBgCAT(ABx-Sm) construct exhibited only 34% of the
wild-type response. Another downstream deletion mutant,
pMBg(AHd-Xh), was also relatively nonresponsive to Myb
induction (22% of wild-type response). This plasmid deletes
a region of the noncoding first exon between +148 and +515
which includes the P2 start site and most of the downstream
sequence. Deletion of P2 in pMBgCAT(2-36) did not produce
a decrease in CAT expression. This is in accord with a
previous report (2) which showed that this same deletion
increases the constitutive activity of the P1 promoter. It is
likely that P1 compensates for the P2 deletion.
To further localize the response region within the first
exon, either half of this + 148 to +515 region was deleted. In
this representative experiment (Fig. 3B), deletion of either
half had no significant effect compared with deletion of both
halves, which was only 33% as active as the wild type. These
data suggest that either half can compensate for the other, as
confirmed by later mutagenesis studies (see Tables 2 and 3).
In Fig. 3B, deletion of the distal MRR between bp -1140 and
-424 (pSmBgCAT plasmid) increased background transcrip-
tion as it decreased Myb induction. This effect was consis-
tent for three different DNA preparations and may reflect the
deletion of a lymphoid-specific dehancer element previously
mapped to this region (44). The dual use of a distal and a
proximal response region was also observed in another
T-cell line, BW5147 (Table 1). These data suggest that the
Myb activation of c-myc in T-cell lines requires two MRRs:
(i) a distal site upstream of the P1 promoter between bp -868
and -424 and (ii) a proximal site including first-exon se-
quences between bp +148 and +515.
Deletion mapping in myelomonocytic WEHI-3 cells reveals
exclusive utilization of the proximal response region. To
determine whether the same MRRs were utilized in other
responder cell types, deletions of the 1.7-kb c-myc fragment
in the pMBgCAT reporter plasmid were assayed for Myb
responsiveness. The myelomonocytic cell line WEHI-3 was
again chosen as an interesting model. As shown in Fig. 4A,
the wild-type pMBgCAT reporter plasmid was stimulated
>30-fold by c-Myb. Unexpectedly, truncation of the distal
bp -1140 to -424 region which defines a distal MRR in EMA
cells had no effect on WEHI-3 cells. This observation was
confirmed four times. The MRR in WEHI-3 cells could be
mapped to the first noncoding exon, as shown by Myb's
ability to activate the pMBmBgCAT plasmid, which con-
tains the first exon, but not the exonless pMSmBmCAT
plasmid (Fig. 4A).
To determine whether the MRR in the first exon mapped
to the same proximal bp +148 to +515 site utilized in ELM
cells, the corresponding HindIII-XhoI segment was deleted
and shown to cause a significant loss (95%) of Myb respon-
siveness (Fig. 4B). Deletion of either half of this region
produced little effect, similar to EM4 cells. The utilization of
the -1140 to -424 distal MRR in EML and BW5147 cells but
not WEHI-3 cells suggests that Myb activates through this
distal site in a T-cell-specific manner. All other cell types
examined require only the proximal response region of
c-myc for c-Myb trans activation (Table 1).
The first exon of c-myc is sufficient to confer Myb respon-
siveness to a heterologous promoter in WEHI-3 cells but not
ELA cells. Since the proximal site appeared to be an impor-
tant MRR in all cell types, this region was separated from the
rest of the c-myc promoter and tested for its ability to confer
Myb responsiveness to an enhancerless test plasmid. The
plasmid pSVM(H)RCAT contains the HindIII-to-BglII frag-
ment of c-myc's first exon cloned in its natural orientation
downstream of the SV40 promoter. Myb induction of the
pSVM(H)RCAT reporter plasmid was compared between
EMA and WEHI-3 cells (Fig. 5) by using a 1:1 ratio of
expression vector to reporter plasmid. pSVM(H)RCAT was
effectively activated by c-Myb in WEHI-3 cells (18.4-fold)
but weakly (3-fold) in ELM cells. A control test plasmid
which only contains the SV40 promoter was activated less
than twofold in both cell types. In the same experiments in
EL4 cells, Myb stimulated the full-length c-myc promoter
test plasmid, pMBgCAT, which contains both MRRs. The
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FIG. 3. Myb trans activation of mutated c-myc-CAT reporter genes in lymphoid EM4 cells. A map of the wild-type c-myc-CAT construct
is shown at the top of each panel. The P1 and P2 transcription start sites are marked with bent arrows. The first noncoding exon is marked
by a shaded box. The positions of 16 putative Myb-binding sites are shown. Mutant reporter genes are listed in the far right column. Lines
to the left of each plasmid name represent the promoter sequences present in each construct. Wild-type (pMBgCAT) and mutant reporter
genes were cotransfected with wild-type Myb expression vector pRmb3SVneo (+) or a frameshift mutant, pJTmyb-fs (-). Percent acetylation
(%Ac) of the 14C-chloramphenicol substrate was measured, and the Myb-specific trans activation (xT) was calculated as the ratio of %Ac with
pRMb3SVneo/%Ac with pJTmyb-fs. Relative trans activation (%T) was calculated from the Myb-specific trans activations for the mutant
reporter relative to 100% for the wild-type pMBgCAT reporter. (A) A summary of multiple experiments in which %T was normalized to the
wild-type vector included in every experiment. The average %Ac for pMBgCAT was 3.5% in the absence of Myb and 42% in the presence
of Myb. (B) Results of a representative experiment with EL4 cells which maps two MRRs in EL4 cells. Maps are not drawn to scale. See
text for details.
BgIII-SmaI distal MRR did not confer Myb responsiveness
to an enhancerless test plasmid in either cell line (data not
shown). These data confirm that a HindIII-BglII fragnent of
the first exon is sufficient as a Myb-inducible element in
WEHI-3 cells but not in EL4 cells.
Site-specific mutagenesis of potential Myb-binding sites. To
finely map the MREs in the c-myc promoter, potential
Myb-binding sites from Fig. 2 were selected and mutated.
This endeavor has been fraught with difficulties because of
the large number of potential c-Myb-binding sites in this
promoter. Furthermore, mutation of single or even a few
sites has little effect on c-Myb trans activation (see below).
Most of the efforts have been devoted to the Myb target sites
in the first exonic region because (i) this region is important
in all cell types tested, (ii) the effect is consistently large and
not variable between experiments, and (iii) fewer c-Myb
targets are involved, making the mutagenesis scheme more
feasible. Five different potential sites were identified (sites
11 to 15 in Fig. 2) in this region. In three different experi-
ments with EIA cells, significant residual activity was ob-
served when one to four of these sites were mutated, and
mutation of all five sites was essential for the near oblitera-
tion of Myb trans-activating activity (Tables 2 and 3). This
strongly suggests that many of these sites may be redundant
and agrees with data shown earlier in Fig. 3B and 4B. Similar
results were observed in WEHI-3 cells (data not shown).
Site-specific mutations were also made in the upstream sites.
Mutation of sites 3 through 6 created little change in c-Myb
trans activation (data not shown). It is likely that all of the
upstream sites have to be simultaneously mutated to pro-
duce an effect.
Deletion mutants of the c-Myb protein reveal functional
domains for activation of c-myc gene expression. The previous
data suggest that the c-myc promoter contains two larger
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FIG. 4. Myb trans activation of mutated c-myc CAT reporter genes in myelomonocytic WEHI-3 cells. See the legend to Fig. 3 for an
explanation of the map. Panels show results of representative experiments which map the Myb response to a proximal site in the c-myc first
exon.
MRRs and that each MRR contains several potential Myb-
binding sites. The loss of Myb responsiveness associated
with mutagenesis of the first-exon MREs implicates DNA
binding. Recombinant v-Myb also binds to this region in a
gel shift assay (data not shown). To further assess the DNA
binding requirement, mutant c-Myb proteins were assayed
for their ability to trans activate the wild-type c-myc reporter
gene. Figure 6A shows the c-Myb protein with the locations
of its three regulatory domains: the DNA-binding domain,
the trans-activator domain, and the negative regulatory
domain. ATA contains an internal deletion of the trans
activator domain. ABALI has a carboxyl-terminal truncation
which removes the trans activator domain but retains the
DNA-binding domain. W- G contains a point mutation
which replaces the last tryptophan in the R3 domain (amino
acid 185) with a glycine and affects the ability of this mutant
protein to bind DNA (45).
EL4 cells were transfected with the wild-type or mutant
Myb expression vectors and pMBgCAT, and the results of
three experiments were averaged (Fig. 6B). The wild-type
expression vector, pRmb3SVneo, elicited 23.4- and 51.5-fold
activations at 1:1 and 2:1 ratios of Myb expression vector
pMBgCAT, respectively. pMBgCAT was trans activated
only twofold by the W- G mutant, suggesting that trans
activation was dependent on DNA-binding function. ATA
was approximately 15% as active as wild-type Myb expres-
sion vector. The significant eightfold activation at the 2:1
ratio suggests that other regions of the protein may have
weak trans-activator function or that Myb function is cou-
pled to other proteins with activator function in EM4 cells.
The expression of all the mutant proteins was confirmed by
immunoprecipitation analyses (data not shown). Parallel
studies with WEHI-3 cells showed similar requirements for
the DNA-binding and trans-activator domains with the fol-
lowing exception: ATA was not able to trans activate c-myc
at all in WEHI-3 cells (data not shown).
To independently assess the necessity for DNA binding in
c-myc activation, nonfunctional mutants ABALI and W--G
were cotransfected with pRmb3SVneo into EL4 and as-
sessed for their ability to trans-dominantly repress activation
by wild-type Myb protein (Fig. 6C). The ABALI mutant,
which encodes the DNA-binding domain of c-Myb, would be
expected to produce proteins which saturate DNA-binding
sites in vivo and prevent binding by wild-type c-Myb pro-
tein. In two independent experiments, ABALI repressed
activation by wild-type c-Myb to 52 and 27% of control
values; the average result of both experiments (39% of
































FIG. 5. Myb trans activation of a heterologous promoter containing the c-myc first exon sequence. Maps of the wild-type pMBgCAT
reporter plasmid, heterologous promoter test plasmid pSVM(H)RCAT, and control enhancerless SV40 promoter are shown. Bg, BglII; Hd,
HindIll. These reporter genes were cotransfected at 1:1 ratios with wild-type or frameshift mutant Myb expression vectors. Myb-specific
transactivations elicited in EL4 and WEHI-3 cells were calculated as described in the legend to Fig. 3 and are shown to the right. El and E2
are the transcription start sites for the SV40 promoter. The data are averaged from five experiments each with EL4 and WEHI-3.
ment. These data also suggest that DNA binding is necessary
for the in vivo activation of c-myc gene expression.
Myb activation of c-myc gene expression does not require de
novo protein synthesis in ELA and WEHI cells. Myb activa-
tion of at least one other gene appears to require protein
synthesis (9). While Myb activation of c-myc is in part direct,
we have not excluded a mechanism by which Myb induces
another gene whose product is also necessary for Myb
activation. To analyze the requirement for protein synthesis
in Myb activation of c-myc, a conditional system in which
the hormone-binding domain of the estrogen receptor is
fused near the carboxyl terminus ofAMV v-Myb to produce
a chimeric protein which is hormone responsive was used. In
this construct the last 16 amino acids of the Myb protein are
absent but the rest of the v-Myb coding region is intact.
Previous work has shown that the hormone-binding domains
of steroid receptors exhibit hormone-dependent inactivation
functions and that their fusion to heterologous proteins
makes these proteins hormone dependent (9, 41).
Estrogen-dependent activation of Myb-regulated genes
had been studied only in stable transfectants (9); it was
important to determine whether this system would work in a
transient expression system. Likewise, the only available
v-Myb-estrogen receptor test construct (constructed by
U.E. in the laboratory of Joe Lipsick) contains an additional
amino-terminal deletion as well as several mutations com-
pared with c-Myb. We cotransfected a v-Myb-estrogen
receptor expression vector along with the wild-type pMBg-
CAT reporter and allowed 24 h for the synthesis and
accumulation of the fusion protein. The cells were treated
TABLE 2. Site-specific mutagenesis of Myb-binding sites






a Refer to Fig. 2.
b Underlinings represent mutated base pairs.
with 1 ,uM -estradiol, and CAT activity was measured after
an additional 24 h (Fig. 7A). Prior to estrogen induction, a
control expression vector encoding wild-type AMV v-Myb
protein (pNEO-AMV) showed strong induction of the c-myc
promoter while an empty expression vector (pNeo-MAV-
CLA) or the Myb-estrogen expression vector (pNEO-
Myb-E) elicited low CAT activities. Addition of estrogen
strongly activated the chimeric protein's ability to activate
c-myc, as shown by the 10-fold increase in CAT activity.
Estrogen addition had no effect on either control (the result
of a CAT assay under conditions of nonlimiting substrate is
shown in parentheses for pNEO-AMV). Thus, Myb activa-
tion of the c-myc promoter has been made estrogen depen-
dent for pNEO-Myb-E through linkage of the ligand-binding
domain of estrogen receptor to v-Myb protein. The ability of
v-Myb itself to activate c-myc also suggests that a truncated
and transforming Myb protein is still capable of activating
c-myc gene expression.
To determine whether c-myc could be activated by c-Myb
in the absence of de novo protein synthesis, we cotrans-
fected pNEO-Myb-E with the pMyc-globin reporter and
measured estrogen induction of c-myc mRNA in the pres-
ence and absence of cycloheximide. After 24 h to allow
accumulation of the fusion protein, cycloheximide was
added to test cultures 20 min prior to the addition of
estrogen. After an additional 5 h, RNA was harvested and
analyzed by Si protection analysis. A representative one of
three experiments is shown in Fig. 7B.
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FIG. 6. Myb domains important for c-myc activation in EL4 cells. (A) A model of the c-Myb protein is shown. Regulatory domains are
represented by name (DNA, DNA-binding domain; TA, trans-activator domain; NR, negative regulatory domain), and their locations are
revealed as shaded boxes. Arrows marked Rl, R2, and R3 show the location of the triple repeat structure. The circle labelled CKII shows
the amino-terminal location of important CKII phosphorylation sites. Lines marked NLS and LZ show locations of putative nuclear
localization and leucine zipper motifs. Mutant Myb proteins are represented by names to the left and by lines below the model. The deleted
domains are represented by gaps in the lines. (B) A bar graph summary of three experiments with EL4 using these Myb mutants to trans
activate expression from pMBgCAT is shown. The ratios of c-Myb expression vector to c-myc CAT reporter construct are on the left.
Myb-specific trans activations (xT) are shown to the right of each bar. Lines through the center of each bar show standard errors. (C) Use
of trans-dominant mutants to show that DNA binding is necessary for inducing c-myc gene expression. A bar graph summary of two
experiments is shown. Nonfunctional c-Myb mutant expression vectors (i.e., W-+G, ABALI, and frameshift mutant [FS]) were cotransfected
1:1 with wild-type (WT) Myb expression vectors into EL4 cells, and CAT activity (expressed as percent acetylation [%Ac]) of the pMBgCAT
reporter gene was measured. ABALI repressed activation by the WT Myb to 39% of control (WT + FS).
In EL4 cells, a 5-h estrogen induction induced approxi-
mate fourfold and twofold increases in P1- and P2-initiated
c-myc transcripts, respectively, as determined by densito-
metric measurements (Fig. 7B, lane 1 versus lane 2). This
degree of induction was lower than that observed in Fig. 1
because some Myb protein was made in the absence of
estrogen induction, thus contributing to a high baseline.
Nonetheless, treatment with cycloheximide did not signifi-
cantly affect the level of c-myc (Fig. 7B, lane 3). Induction
with estrogen in the presence of cycloheximide resulted in
equivalent enhancement of mRNA levels to those of the
samples treated with cycloheximide alone (lane 4). Again,
the Myb protein appeared not to affect endogenous c-myc
levels (lanes 1 to 4). These data indicated that Myb induction
in EL4 cells does not require additional de novo protein
synthesis. Similar studies were performed with WEHI-3
cells with similar results (data not shown).
DISCUSSION
Myb activation of c-myc gene expression involves a po-
tentially important regulatory cascade in vivo between two
proto-oncogene transcription factors. Myb and Myc each
share a common function in that they control cell prolifera-
tion and differentiation (13, 31, 32, 48). Their linked expres-
sion is probably not related to coexpression, since c-Myb
and c-Myc are not known to interact with each other. c-Myc
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FIG. 7. Estrogen-dependent activation of c-myc-CAT expression by Myb-estrogen receptor fusion protein in EL4 cells. (A) The effect of
estrogen addition (+) or exclusion (-) on the activation of pMBgCAT reporter plasmid by Myb-less control (pNEO-MAV-CLA), wild-type
AMV (pNEO-AMV), and AMV-estrogen receptor (pNEO-Myb-E) expression vectors is assessed by CAT enzyme assay. A representative
experiment with ELM cells demonstrating estrogen-dependent activation of Myb-estrogen receptor activity is shown. Percent acetylations
(%Ac) are listed on the right. Numbers in parentheses are values obtained when samples were repeated under conditions of nonlimiting
substrate. (B) Si nuclease protection analysis. Cells cotransfected with pNEO-Myb-E and pMyc-globin were (lane 2 and 4) or were not (lanes
1 and 3) treated with estrogen. Lanes 3 and 4 were treated with cycloheximide; lanes 1 and 2 were not treated with the inhibitor. See the legend
to Fig. 1 for an explanation of S1 nuclease protection analysis and size of RNA-probe hybrids.
the helix-loop-helix/leucine zipper class of transcription fac-
tors (8, 43), while Myb partners are not yet known. We
hypothesize that c-Myb plays a central role in the control of
hematopoietic cell proliferation and differentiation through
its ability to regulate c-myc gene expression. An argument
against this possibility is the finding that c-myc usually
precedes c-myb expression. However, recent evidence in
Drosophila cells shows that the functional effect of c-Myb is
observed as late as the G2 phase of the cell cycle (27a). An
attractive possibility is that c-Myb from a previous cell cycle
is up-regulating c-myc gene expression in the following
cycle.
Those cell types which were most permissive (i.e., al-
lowed the greatest response) are also those which express
Myb in vivo or are transformed by Myb. For example,
hematopoietic cells, especially immature cells, are the pri-
mary expressors of c-Myb in vivo. Likewise, myelomono-
cytic and B-lymphoid cells are transformed by avian leuke-
mia viruses or by retroviral insertion into the Myb locus (25,
27, 42). The observation that some cell types are relatively
nonresponsive despite our provision of a Myb expression
vector (Table 1) suggests that mere expression of c-Myb is
not sufficient to drive c-myc gene expression. Perhaps cell-
specific factors modify Myb's function or restrict the c-myc
promoter's ability to be activated. We suggest that these
cell-specific factors facilitate Myb's ability to activate c-myc
and ultimately control cell proliferation and differentiation or
the process of Myb transformation.
Whether the cell type controls Myb activation by modify-
ing Myb itself or facilitating c-myc's ability to be activated is
unknown. Experiments presented here revealing a cell-type-
specific use of MREs between T cells and other cell types
suggest the latter. Myb activation of c-myc in EMA and
BW5147 cells requires both proximal and distal response
regions (Fig. 3 and Table 1). We additionally have seen that
virtually all activation in WEHI-231 and WEHI-3 cells
occurs through the proximal region (data summarized in
Table 1). These data show that c-myc's first exon is an
important MRR in all cell types but that the region upstream
of the P1 start site promotes Myb activation in T cells. The
observation that the HindIII-BglII first-exon fragment is
sufficient to confer Myb responsiveness to a heterologous
promoter in WEHI-3 but not ELM cells (Fig. 5) supports this
notion of response region preference. However, our demon-
stration that mutations in the proximal region binding sites
block Myb trans activation suggests that the first exon is
necessary but not sufficient for the Myb response in T cells.
Despite cell-specific influences, data presented here sug-
gests that Myb's effect involves binding to Myb consensus
elements in the c-myc first exon. Prior to this study, a direct
link between the presence of Myb regulatory elements and
trans activation by Myb has been established only for the
mim-1 and human c-myb genes (39, 40). A necessity for
DNA binding by Myb is shown here by demonstrations that
the DNA-binding domain of the c-Myb protein is necessary
for Myb function and that mutagenesis of putative Myb-
binding sites within c-myc's first exon blocks trans activa-
tion. The DNA-binding domain of c-Myb was also shown to
be necessary for activation of the human c-myc gene (36),
but this is the first demonstration linking Myb activation to
specific binding sites. Cofactor requirements are potentially
indicated for the Hsp7O gene, in which Myb regulation
occurs in the absence of DNA binding (28), and for the MD-1
gene, in which de novo protein synthesis is required for Myb
regulation (9). For this reason we used a conditional system
to test whether Myb could activate c-myc in the absence of
de novo protein synthesis (Fig. 7). These data suggest that
Myb can activate c-myc in the absence of de novo protein
synthesis and that labile proteins which modulate basal
c-myc transcription are not linked to the Myb activation
pathway (38). These experiments do not rule out cofactors
with long half-lives. We suggest that if these cofactors exist,
they are cell specific and influence how Myb interfaces with
c-myc. These factors may modify Myb itself by posttransla-
tional modification or behave as coactivator proteins on the
c-myc promoter.
Which c-myc transcripts are induced by Myb has not been
reported previously. In this paper we show that c-Myb
appears to show little promoter preference in activating
c-myc transcription. Previous work suggests that the P1 and
P2 promoters of c-myc are regulated independently (2, 58).
Elements within the first 100 bp upstream of P1 affect P1
activity, while elements in the first exon sequence upstream






2868 COGSWELL ET AL.
would be expected to influence P1 transcription, the findings
that WEHI-3 cells utilize only the proximal MRR and that
Myb stimulates both P1 and P2 transcripts suggest that
elements downstream of P2 affect both promoters. This is
consistent with previous evidence showing that the first exon
contains a position- and orientation-dependent element
which can promote transcription from both the El and E2
start sites of the SV40 promoter contained in the pSVM(H)R-
CAT test plasmid (58). It is possible that Myb regulates the
function of this positive control element.
In conclusion, this report shows that activation of the P1
and P2 promoters of murine c-myc by Myb is dependent on
a distal upstream region and DNA within the first exon of
c-myc in T cells while only the first exon region is necessary
in other cells. Both of these regions contain functional
Myb-binding sites. Myb's activity in this system is mediated
by two domains, the DNA-binding and trans-activator do-
mains. In addition to Myb, other labile proteins do not play
a role in this process. These studies have elucidated many
features of the trans activation of c-myc by Myb which
serves as a model for the function of Myb in biologically
important systems.
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